ES2717680T3 - Potenciador de inhibidores del homólogo de Zeste 2 - Google Patents
Potenciador de inhibidores del homólogo de Zeste 2 Download PDFInfo
- Publication number
- ES2717680T3 ES2717680T3 ES14727619T ES14727619T ES2717680T3 ES 2717680 T3 ES2717680 T3 ES 2717680T3 ES 14727619 T ES14727619 T ES 14727619T ES 14727619 T ES14727619 T ES 14727619T ES 2717680 T3 ES2717680 T3 ES 2717680T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- alkyl
- oxo
- carboxamide
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCN(C1CCOCC1)c1c[s]c(C(NCC2=C(C)C=C(C)NC2=O)=*)c1C Chemical compound CCN(C1CCOCC1)c1c[s]c(C(NCC2=C(C)C=C(C)NC2=O)=*)c1C 0.000 description 11
- PCJPGNCABBDNJU-UHFFFAOYSA-N CC(C=C(C)N1)=C(CN)C1=O Chemical compound CC(C=C(C)N1)=C(CN)C1=O PCJPGNCABBDNJU-UHFFFAOYSA-N 0.000 description 2
- SPAMOVMQVZRCLQ-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C(CC2)CN2C(OC(C)(C)C)=O)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C(CC2)CN2C(OC(C)(C)C)=O)[s]1 SPAMOVMQVZRCLQ-UHFFFAOYSA-N 0.000 description 2
- DLMDCJCZDYNJSD-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(CCC1)N1c1c(C)c(C(O)=O)c[s]1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(CCC1)N1c1c(C)c(C(O)=O)c[s]1)=O DLMDCJCZDYNJSD-UHFFFAOYSA-N 0.000 description 1
- IHTOYNHWGNUOPL-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)=O)=O IHTOYNHWGNUOPL-UHFFFAOYSA-N 0.000 description 1
- HFPTVKCVVCVGRX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(c1c(C)c(C(OC)=O)c[s]1)O)=O HFPTVKCVVCVGRX-UHFFFAOYSA-N 0.000 description 1
- HWTFKGHPEWQQLA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(NCC3=C(C)C=C(C)NC3=O)=O)c[s]2)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(NCC3=C(C)C=C(C)NC3=O)=O)c[s]2)c1)=O HWTFKGHPEWQQLA-UHFFFAOYSA-N 0.000 description 1
- HROLHLXMGDWYKN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(O)=O)c[s]2)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1[n]1ncc(-c2c(C)c(C(O)=O)c[s]2)c1)=O HROLHLXMGDWYKN-UHFFFAOYSA-N 0.000 description 1
- RMFDEPMDYYFJQT-UHFFFAOYSA-N CC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)N1CCOCC1 Chemical compound CC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)N1CCOCC1 RMFDEPMDYYFJQT-UHFFFAOYSA-N 0.000 description 1
- QRWJPHCVNZHHNB-UHFFFAOYSA-N CC(c1c(C)c(C(OC)=O)c[s]1)N1CCOCC1 Chemical compound CC(c1c(C)c(C(OC)=O)c[s]1)N1CCOCC1 QRWJPHCVNZHHNB-UHFFFAOYSA-N 0.000 description 1
- FPCYGYXSPUZDQR-UHFFFAOYSA-N CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C1CCN(C)CC1 Chemical compound CCC(c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c[s]1)=C1CCN(C)CC1 FPCYGYXSPUZDQR-UHFFFAOYSA-N 0.000 description 1
- RQWZJZLXHIPBPL-UHFFFAOYSA-N CCC(c1c(C)c(C(OC)=O)c[s]1)=O Chemical compound CCC(c1c(C)c(C(OC)=O)c[s]1)=O RQWZJZLXHIPBPL-UHFFFAOYSA-N 0.000 description 1
- DASMNPQOGKWRPR-UHFFFAOYSA-N CCC(c1c(C)c(C(OC)=O)c[s]1)O Chemical compound CCC(c1c(C)c(C(OC)=O)c[s]1)O DASMNPQOGKWRPR-UHFFFAOYSA-N 0.000 description 1
- CJIZFOICFTVTGK-UHFFFAOYSA-N CCN(C1CCCCC1)c1c(C)c(C(OC)=[U])c(C#N)[s]1 Chemical compound CCN(C1CCCCC1)c1c(C)c(C(OC)=[U])c(C#N)[s]1 CJIZFOICFTVTGK-UHFFFAOYSA-N 0.000 description 1
- DPMPQZDRSNAUCN-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c(-c2c[o]cc2)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)c(-c2c[o]cc2)[s]1 DPMPQZDRSNAUCN-UHFFFAOYSA-N 0.000 description 1
- IESJTEZXBWQDBI-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)n[n]1C Chemical compound CCN(C1CCOCC1)c1c(C)c(C(NCC2=C(C)C=C(C)NC2=O)=O)n[n]1C IESJTEZXBWQDBI-UHFFFAOYSA-N 0.000 description 1
- MAAOIQTZRFMBBT-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(O)=O)c(C(CC2)CN2C(OC(C)(C)C)=O)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(O)=O)c(C(CC2)CN2C(OC(C)(C)C)=O)[s]1 MAAOIQTZRFMBBT-UHFFFAOYSA-N 0.000 description 1
- CGJODYOOVBWYST-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(O)=O)c[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(O)=O)c[s]1 CGJODYOOVBWYST-UHFFFAOYSA-N 0.000 description 1
- GOCTVGJPYJGVGA-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C(C2)=CCN2C(OC(C)(C)C)=O)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(C(C2)=CCN2C(OC(C)(C)C)=O)[s]1 GOCTVGJPYJGVGA-UHFFFAOYSA-N 0.000 description 1
- IGYRPGJLRYHDLG-UHFFFAOYSA-N CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(N2CCN(C)CC2)[s]1 Chemical compound CCN(C1CCOCC1)c1c(C)c(C(OC)=O)c(N2CCN(C)CC2)[s]1 IGYRPGJLRYHDLG-UHFFFAOYSA-N 0.000 description 1
- QHNQZPFKGBKHQM-UHFFFAOYSA-N CCN(CC)c1c(C)c(C(OC)=O)c[s]1 Chemical compound CCN(CC)c1c(C)c(C(OC)=O)c[s]1 QHNQZPFKGBKHQM-UHFFFAOYSA-N 0.000 description 1
- CGSHLYMSAJDNCC-UHFFFAOYSA-N CCc1c(C(OC)=O)c(C)c(N(CC)C2CCOCC2)[s]1 Chemical compound CCc1c(C(OC)=O)c(C)c(N(CC)C2CCOCC2)[s]1 CGSHLYMSAJDNCC-UHFFFAOYSA-N 0.000 description 1
- ZTDYZXWQADNRRI-UHFFFAOYSA-N Cc1c(C(OC)=O)[s]cc1Br Chemical compound Cc1c(C(OC)=O)[s]cc1Br ZTDYZXWQADNRRI-UHFFFAOYSA-N 0.000 description 1
- JXASDTULWFSTGQ-UHFFFAOYSA-N Cc1c(C)[nH]cc1C(OC)=O Chemical compound Cc1c(C)[nH]cc1C(OC)=O JXASDTULWFSTGQ-UHFFFAOYSA-N 0.000 description 1
- QDPUOXFZEKRPQG-UHFFFAOYSA-N Cc1c(C)[s]c(Br)c1C(OC)=O Chemical compound Cc1c(C)[s]c(Br)c1C(OC)=O QDPUOXFZEKRPQG-UHFFFAOYSA-N 0.000 description 1
- CQZPEBDZIWYWEL-UHFFFAOYSA-N Cc1c(N)[s]cc1C(OC)=O Chemical compound Cc1c(N)[s]cc1C(OC)=O CQZPEBDZIWYWEL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817436P | 2013-04-30 | 2013-04-30 | |
| US201361842038P | 2013-07-02 | 2013-07-02 | |
| US201361907024P | 2013-11-21 | 2013-11-21 | |
| US201461936460P | 2014-02-06 | 2014-02-06 | |
| PCT/IB2014/061012 WO2014177982A1 (en) | 2013-04-30 | 2014-04-25 | Enhancer of zeste homolog 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717680T3 true ES2717680T3 (es) | 2019-06-24 |
Family
ID=50877537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14727619T Active ES2717680T3 (es) | 2013-04-30 | 2014-04-25 | Potenciador de inhibidores del homólogo de Zeste 2 |
Country Status (20)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ628762A (en) * | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EA030196B1 (ru) * | 2013-04-30 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Ингибиторы энхансера zeste гомолога 2 |
| RU2016104044A (ru) | 2013-07-10 | 2017-08-15 | Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед | Ингибиторы усилителя zeste гомолога 2 |
| RS65894B1 (sr) | 2014-02-06 | 2024-09-30 | Nxera Pharma Uk Ltd | Biciklična aza jedinjenja kao agonisti muskarinskog receptora |
| CA2965729A1 (en) * | 2014-10-28 | 2016-05-06 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| TW201636344A (zh) * | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Ｚｅｓｔｅ同源物２增強子之抑制劑 |
| CA2996412A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| JP2018532761A (ja) * | 2015-11-06 | 2018-11-08 | エピザイム，インコーポレイティド | Ｅｚｈ２阻害剤を用いた癌の処置のための小児投与 |
| US10759787B2 (en) | 2015-11-19 | 2020-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofuran derivative, preparation method thereof and use thereof in medicine |
| CN109328188A (zh) * | 2016-05-05 | 2019-02-12 | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | Zeste增强子同源物2抑制剂 |
| US20170337814A1 (en) * | 2016-05-20 | 2017-11-23 | Donald Edward Morgan | Safety alerting drivers device and system |
| JP6816287B2 (ja) | 2016-09-07 | 2021-01-20 | シャンハイ ハイヘ ファーマシューティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｈｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ | ピリジン並びに５員芳香環系化合物、その製造方法及び使用 |
| US20190367457A1 (en) | 2016-12-30 | 2019-12-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| CA3089639C (en) | 2018-01-31 | 2024-06-18 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| TWI762939B (zh) * | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110964200A (zh) * | 2019-12-19 | 2020-04-07 | 新纳奇材料科技江苏有限公司 | 一种基于聚硅氧烷馏出物的羟基封端聚硅氧烷的制备方法 |
| WO2021129629A1 (zh) * | 2019-12-23 | 2021-07-01 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080293716A1 (en) * | 2004-01-30 | 2008-11-27 | Smithkline Beecham Corporation | Chemical Compounds |
| RU2006138036A (ru) * | 2004-03-30 | 2008-05-10 | Чирон Корпорейшн (Us) | Производные замещенного тиофена в качестве противораковых средств |
| US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| BR112012002336A2 (pt) * | 2009-08-07 | 2016-05-31 | Merck Patent Gmbh | compostos aza-heterocíclicos |
| US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| WO2011140325A1 (en) * | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2760452A4 (en) * | 2011-09-30 | 2015-04-01 | Glaxosmithkline Llc | METHODS OF TREATING CANCER |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| KR20220123339A (ko) | 2012-04-13 | 2022-09-06 | 에피자임, 인코포레이티드 | 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| EA030196B1 (ru) * | 2013-04-30 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед | Ингибиторы энхансера zeste гомолога 2 |
-
2014
- 2014-04-25 EA EA201592068A patent/EA030196B1/ru not_active IP Right Cessation
- 2014-04-25 AU AU2014261075A patent/AU2014261075B2/en not_active Ceased
- 2014-04-25 JP JP2016511152A patent/JP6373973B2/ja not_active Expired - Fee Related
- 2014-04-25 SG SG11201508203TA patent/SG11201508203TA/en unknown
- 2014-04-25 CN CN201480033093.6A patent/CN105308038B/zh not_active Expired - Fee Related
- 2014-04-25 KR KR1020157033651A patent/KR20160003115A/ko not_active Application Discontinuation
- 2014-04-25 MX MX2015015144A patent/MX2015015144A/es unknown
- 2014-04-25 US US14/787,866 patent/US9505745B2/en active Active
- 2014-04-25 NZ NZ630205A patent/NZ630205A/en not_active IP Right Cessation
- 2014-04-25 WO PCT/IB2014/061012 patent/WO2014177982A1/en active Application Filing
- 2014-04-25 CA CA2910873A patent/CA2910873A1/en not_active Abandoned
- 2014-04-25 PE PE2015002298A patent/PE20151981A1/es not_active Application Discontinuation
- 2014-04-25 ES ES14727619T patent/ES2717680T3/es active Active
- 2014-04-25 EP EP14727619.0A patent/EP2991980B1/en active Active
- 2014-04-25 BR BR112015027527A patent/BR112015027527A2/pt not_active IP Right Cessation
-
2015
- 2015-10-06 ZA ZA2015/07398A patent/ZA201507398B/en unknown
- 2015-10-19 PH PH12015502414A patent/PH12015502414A1/en unknown
- 2015-10-30 CL CL2015003200A patent/CL2015003200A1/es unknown
- 2015-10-30 DO DO2015000270A patent/DOP2015000270A/es unknown
-
2016
- 2016-03-09 HK HK16102708.1A patent/HK1214815A1/zh unknown
- 2016-10-13 US US15/292,200 patent/US9790212B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20160102083A1 (en) | 2016-04-14 |
| JP2016517878A (ja) | 2016-06-20 |
| AU2014261075A1 (en) | 2015-11-05 |
| NZ630205A (en) | 2017-03-31 |
| CN105308038A (zh) | 2016-02-03 |
| CN105308038B (zh) | 2018-05-29 |
| SG11201508203TA (en) | 2015-11-27 |
| EP2991980A1 (en) | 2016-03-09 |
| WO2014177982A1 (en) | 2014-11-06 |
| HK1214815A1 (zh) | 2016-08-05 |
| CA2910873A1 (en) | 2014-11-06 |
| PH12015502414A1 (en) | 2016-02-22 |
| MX2015015144A (es) | 2016-02-18 |
| JP6373973B2 (ja) | 2018-08-15 |
| DOP2015000270A (es) | 2016-02-15 |
| KR20160003115A (ko) | 2016-01-08 |
| EA030196B1 (ru) | 2018-07-31 |
| ZA201507398B (en) | 2017-01-25 |
| EA201592068A1 (ru) | 2016-05-31 |
| PE20151981A1 (es) | 2016-01-14 |
| AU2014261075B2 (en) | 2017-01-19 |
| BR112015027527A2 (pt) | 2017-07-25 |
| US9505745B2 (en) | 2016-11-29 |
| US9790212B2 (en) | 2017-10-17 |
| US20170029412A1 (en) | 2017-02-02 |
| EP2991980B1 (en) | 2019-01-02 |
| CL2015003200A1 (es) | 2016-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717680T3 (es) | Potenciador de inhibidores del homólogo de Zeste 2 | |
| AU2017283790B2 (en) | Substituted pyridines as inhibitors of DNMT1 | |
| JP5864546B2 (ja) | インダゾール | |
| AU2013371541B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| AU2014276417B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| AU2014288839B2 (en) | Enhancer of Zeste Homolog 2 inhibitors | |
| AU2015340614B2 (en) | Enhancer of zeste homolog 2 inhibitors | |
| ES2804749T3 (es) | Inhibidores de EZH2 (potenciador del homólogo Zeste 2) | |
| NZ747748A (en) | Substituted pyridines as inhibitors of dnmt1 |